Genito-Urinary Drugs Global Market Report 2018

1. Genito-Urinary Drugs Global Market Report 2018 Including: Hormonal contraceptives; Drugs For Hormonal Replacement Therapy; Drugs For Infections And Others; Drugs for Benign prostatic hypertrophy; Drugs For Erectile Dysfunction; Drugs For Urinary Incontinence And Overactive Bladder; Drugs for Infertility; Diuretics Covering: Daiichi Sankyo Company Limited, Pfizer Inc., Bayer AG, Astellas Pharma Inc., Allergan Plc Feb 2018

2. Reasons to Purchase • Outperform competitors using accurate up to date demand-side dynamics information. • Identify growth segments for investment. • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market. • Create regional and country strategies on the basis of local data and analysis. • Stay abreast of the latest customer and market research findings • Benchmark performance against key competitors. • Develop strategies based on likely future developments. • Utilize the relationships between key data sets for superior strategizing. • Suitable for supporting your internal and external presentations with reliable high quality data and analysis • Gain a global perspective on the development of the market. • Report will be updated with the latest data and delivered to you within 3-5 working days of order. Scope Markets Covered: Hormonal contraceptives; Drugs For Hormonal Replacement Therapy; Drugs For Infections And Others; Drugs for Benign prostatic hypertrophy; Drugs For Erectile Dysfunction; Drugs For Urinary Incontinence And Overactive Bladder; Drugs for Infertility; Diuretics Companies Mentioned: Daiichi Sankyo Company Limited, Pfizer Inc., Bayer AG, Astellas Pharma Inc., Allergan Plc Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia. Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast. Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, Genito-Urinary Drugs Indicators Comparison. Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments. Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

3. Genito Genito- -Urinary Drugs Urinary Drugs Market Characteristics Characteristics Market The genitourinary drugs market covers drugs that are used in the treatment of diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, reno vascular diseases, benign prostate diseases, and other related diseases. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing. Genito-urinary disorders include the following – Hormonal contraceptives are medicines that Hormone Replacement Therapy is a treatment used Infections are caused by disease causing microbes such as Benign prostatic hypertrophy is the enlargement of Erectile Dysfunction also known as impotence, is a Urinary incontinence and overactive bladder is the involuntary leakage of Infertility is defined as not being able to Diuretics are medicines that

4. In this report market value is defined as the revenues organizations earn by selling their goods and services within the specified market, based on the price at which they sell. Only goods and services traded between entities are included. The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.

5. Genito Genito- -Urinary Drugs Urinary Drugs Market Historic Growth Historic Growth Market The global genito-urinary drugs market grew from $X billion in 2013 to $X billion in 2017 at a compound annual growth rate (CAGR) of X%. The chart and table below shows the year-on-year growth of the global genito- urinary drugs market during 2013 – 2017. Drivers of the Market: Restraints on the Market:

6. Genito Genito- -Urinary Drugs Urinary Drugs Market Forecast Growth Forecast Growth Market The global genito-urinary drugs market is expected to grow from $XX billion in 2017 to $80.40 billion in 2021 at a compound annual growth rate (CAGR) of XX%. This growth is mainly due to the growing genitourinary disorders like chronic kidney disease CKD and also going forward, the number of pipeline drugs (ABT-614, Abbott Laboratories and EOS789, Chugai Pharmaceutical) are expected to increase with constant improvements in healthcare infrastructure. Novel drugs such as Cialis which are considerably more effective than the drugs used in multiple-drug therapies, and are affordable in cost are expected to fuel the growth of this market. The chart and table below shows the year-on-year growth of the global genito- urinary drugs market during 2017 - 2021. Drivers of the Market: Restraints on the Market:

7. Genito Genito- -Urinary Drugs Urinary Drugs Market Segmentation Segmentation Market The chart and table below shows the split of the genito-urinary drugs market in 2017. The total market value for genito-urinary drugs was $X billion in 2017. The markets that are covered include Hormonal Contraceptives; Drugs For Hormonal Replacement Therapy; Drugs For Infections And Others; Drugs for Benign prostatic hypertrophy; Drugs For Erectile Dysfunction; Drugs For Urinary Incontinence And Overactive Bladder; Drugs for Infertility; Diuretics.

8. Hormonal Contraceptives was the X largest segment in the genito-urinary drugs market with X% share of the market. The market value for the hormonal contraceptives was $X billion in 2017. Drugs For Hormonal Replacement Therapy made up around X% share of the market. The market value for the drugs for hormonal replacement therapy was $X billion in 2017.

9. Genito Genito- -Urinary Drugs Urinary Drugs Market Regional And Country Analysis Regional And Country Analysis Market The Asia Pacific was the largest region in the genito-urinary drugs market in 2017, genito-urinary drugs for $X billion or X% market share. North America was the x largest region genito-urinary drugs for $X billion or X% market share. Western Europe was the x largest region genito-urinary drugs for $X billion or X% market share.

10. Genito Genito- -Urinary Drugs Urinary Drugs Market Competitive Landscape Competitive Landscape Market The leading competitors in the global genito-urinary drugs market are Daiichi Sankyo Company Limited, Pfizer Inc., Bayer AG, Astellas Pharma Inc., Allergan Plc. The chart and table below displays the percentage market share of the top players in the genito-urinary drugs market industry. Daiichi Sankyo Company, Limited generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Pfizer Inc. generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Bayer AG generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. Astellas Pharma Inc generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year.

11. Allergan Plc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Otsuka Pharmaceutical Co., Ltd. generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. GlaxosmithKline Plc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Sanofi S.A. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Company Profile Daiichi Sankyo Company Limited Overview Daiichi Sankyo was the largest competitor in the genito-urinary drugs market in 2017 with XX% market share. Daiichi Sankyo Company is involved in the research, development and marketing of pharmaceutical products for osteoporosis, ulcer treatment, Alzheimer’s disease, anti-influenza treatment, hypertension and diabetes. The company is headquartered in Tokyo, Japan and employs 14,670 people. Products and Services The company operates through following business units – The Sales and Marketing unit is Daiichi Sankyo Espha Co. Ltd. operates its The Vaccine Business unit is responsible for Daiichi Sankyo Healthcare Co. Ltd. develops consumer healthcare products such as

12. Strategy Financial Performance Daiichi Sankyo Company Limited generated revenues of JPY XX billion ($XX billion) in 2015, a XX% increase from the previous year. The company had a market Pfizer Inc. Overview Products and Services Strategy Financial Performance Bayer AG Overview Products and Services Strategy Financial Performance Astellas Pharma Inc. Overview Products and Services Strategy Financial Performance Allergan Plc Overview Products and Services Strategy Financial Performance Daiichi Sankyo Company’s growth strategy aims to expand operations and strengthen product portfolio. The company plans to significantly invest in its locations in New York and Ohio to increase capacity and flexibility to respond to critical market needs. In China, the company is